Charles River Laboratories International and Ship of Theseus announced a Good Manufacturing Practice-plasmid DNA contract development and manufacturing organization agreement. Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate. The collaboration between Charles River and Ship of Theseus will support therapeutic development for a broad variety of target indications such as diabetic and chronic wounds, neutropenia, psoriasis, androgenetic alopecia, women’s health and infertility, and epithelial cancers. Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River extends gene therapy manufacturing alliance with NUS Medicine
- Charles River price target raised to $290 from $200 at Argus
- Charles River and Navega announce an AAV9 production program agreement
- Durect, Charles River enter collaboration agreement for ALZET product line
- Charles River enters pact with Wheeler Bio for Portable CMC platform
